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Abstract Calf spleen pnrine nucleoside phosphorylase was puri- 
fied to homogeneity and its amino acid sequence was determined. 
The complex of the enzyme with an N(7)-acycloguanosine i hib- 
itor crystallized in the cubic space group P213, with unit cell 
dimension a = 94.02 A and one monomer in the asymmetric rys- 
tal unit. The biologically active trimer is formed by the crystallo- 
graphic three-fold axis. The structure was solved by molecular 
replacement methods, using the model of the human erythrocyte 
enzyme, and refined at a resolution of 2.9 A to an R-factor of 
0.21. The orientation of the inhibitor at the active site is examined 
in relation to the catalytic activity of the enzyme in the phosphor- 
olysis of N(7)-fl-o-purine nucleosides. 
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1. Introduction 
Purine nucleoside phosphorylase (PNP, purine nucleoside: 
orthophosphate ribosyltransferase, EC 2.4.2.1) catalyzes the 
reversible phosphorolysis ofpurine ribo and deoxyribo nucleo- 
sides, such as inosine and guanosine in eucaryotes, as well as 
adenosine in some procaryotes, e.g.E, coli, as follows: 
purine nucleoside +phosphate ~ purine base + ribose-l-phosphate 
The high cellular level of this ubiquitous enzyme, and its 
propensity to cleave and inactivate chemotherapeutically ctive 
nucleoside analogues, has led to an intensive search for potent 
inhibitors of the enzyme from various sources [1-9]. Further- 
more, patients with PNP deficiency exhibit marked T-cell im- 
munodeficiency [10,11], and it is considered that PNP inhibitors 
could be useful in treatment of T-cell proliferative diseases, in 
suppression of host versus graft response in organ transplanta- 
tion, and in treatment of T-cell-mediated autoimmune diseases 
[10-12]. 
The enzyme from human erythrocytes has been crystallized, 
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Abbreviations." PNP, purine nucleoside phosphorylase; TFA, trifluoro- 
acetic acid; N7Guo, N(7)-fl-D-ribofuranosylguanine; N7Ino, N(7)-fl-D- 
ribofuranosylhypoxanthine; N(7)-acycloguanosine, 7-[(1,3-dihydroxy- 
propyl-2)amino]ethylguanine; PEG, polyethylene glycol. 
and its structure was determined [13]. Cocrystallization with 
various inhibitors, together with molecular modelling, were 
employed in attempts to develop more potent inhibitors [14- 
16]. These studies uggested that binding of guanine analogue 
inhibitors involves the purine ring N(7) as a hydrogen bond 
acceptor [15]. This is in striking contrast o our finding that a 
variety of N(7)-alkylguanosines, in which the ring N(7) is 
blocked and the imidazole ring carries a positive charge, are 
good substrates, ome even superior to the parent guanosine 
[17-19]. Furthermore, the isomeric N(7)-fl-o-ribosides of hy- 
poxanthine and guanine are substrates, albeit weak ones, of 
mammalian and bacterial PNPs [20]. 
Of further importance are differences in the behaviour of 
PNP from various sources. For example the structural require- 
ments for substrates are quite different for the PNP from E. coli 
or S. typhimurium as compared to that from mammalian 
sources [21 23]. This led to the development of potent inhib- 
itors of the E. coli enzyme which are inactive against calf spleen 
and human erythrocyte PNPs [24]. Differences within mammal- 
ian PNPs are less pronounced, but sufficient o warrant de- 
tailed investigations of their mechanisms of action and behavi- 
our towards inhibitors. 
Here we describe the purification to homogeneity of calf 
spleen PNP, its amino acid sequence, and the crystal structure 
of the enzyme complexed with an acycloguanosine inhibitor in 
which the acyclic chain is located not at the 'natural' conven- 
tional N(9) position, but at the ring N(7). 
2. Experimental and results 
2.1. Mater&& 
Inosine, Tris, citric acid, sodium citrate, sodium phosphate, 
sodium chloride, ammonium carbonate, cyanobromide, tri- 
fluoroacetic acid and acetonitrile were products of Merck 
(Darmstadt, Germany). Sepharose CL-6B was from Pharmacia 
(Uppsala, Sweden); buttermilk xanthine oxidase (1 U/mg), 
trypsin and partially purified calf spleen purine nucleoside 
phosphorylase (-20 U/mg) from Sigma Chemical Co. (St. Louis, 
MO, USA); endoproteinase GLU-C from Boehringer 
Mannheim. The inhibitor 7-[(1,3-dihydroxypropyl-2)-amino]- 
ethylguanine was synthesized as earlier described [20]. 
2.2. Purification of calf spleen PNP 
The commercial enzyme was purified by affinity chromatog- 
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raphy as first described for human erythrocyte PNP [25], with 
all operations at 4°C. The affinity gel consisted of the substrate 
analogue 6-hydroxy-9-p-aminobenzylpurine coupled to Sepha- 
rose CL-6B via trichloro-s-triazine [25]. Following chromatog- 
raphy, PNP substrates (inosine and phosphate) that were used 
to elute the enzyme from the affinity column, as well as the 
products of phosphorolysis (hypoxanthine and ribose-l-phos- 
phate) formed during elution, were removed from the enzy- 
matically active fractions by washing on 30 kDa cut-offAmicon 
filters with 10 mM citrate buffer pH 6.9 + 1 mM fl-mercap- 
toethanol. The washing was continued until the absorbance of 
the effluent was less than 0.01 at 249 nm (maximum of absorb- 
ance of inosine and hypoxanthine). In the final wash, the en- 
zyme solution was concentrated to -20 mg/ml, with specific 
activity 34 U/mg. Gel electrophoresis (Phast system, Pharma- 
cia) exhibited a single band (silver staining), and gel filtration 
(FPLC, Superose 12 Hr 10120 column, Pharmacia) showed one 
symmetric peak. 
Protein concentration was measured spectrophotometrically 
in 50 mM Tris-HC1 buffer pH 7.6, with ~% = ,~2s09.64, similar to 
that for human erythrocyte PNP [26,27]. 
2.3. Sequencing of  calf spleen PNP 
Sequencing of PNP from solution or blotted on polyvi- 
nylidene difluoride membrane via SDS-PAGE revealed that the 
major part of the protein was N-terminal blocked, probably by 
acetylated or acylated methionine. A minor amount of the 
protein had an unblocked N-terminus. The analysis of this 
minor amount of PNP indicated methionine and glutamine in 
positions 1 and 2. Position 3 could not be determined. 
The enzyme was digested with trypsin in 100 mM Tris-HC1 
buffer, pH 8.5 at 37°C over night. Digestion with endopro- 
teinase GLU-C was performed in 25 mM ammonium carbon- 
ate buffer, pH 8.0, at 25°C for 24 h. PNP was cleaved with 
cyanobromide according to [28]. Digestions were checked by 
analytical SDS-PAGE. Peptides were separated on a Vydac C 
18 column, 0.46 x 15 cm, 5/.tm, 300 A (type 218 TP 5415) using 
a gradient system (buffer A: 0.1% TFA/H20; buffer B: 0.1% 
TFA/acetonitrile), gradient o: 5% buffer B, t~Sr, in: 5% buffer B, 
tls0min: 60% buffer B, tZ40min: 80% buffer B; flow rate: 0.5 ml/min; 
37°C (HPLC from Shimadzu/Kyoto; LC-10AD; SCL-10A). 
Sequence analysis of peptides was performed by automatic 
Edman-degradation an Applied-Biosystem (Foster-City, 
CA, USA) gas phase sequencer. Data were analyzed using the 
software 610A Data Analysis Program, Version 1.2. Sequenc- 
ing of peptides from different digests revealed the sequence 
shown in Fig. 1. Relative to the sequence of human PNP, there 
are some amino acid exchanges, and a truncation of 5 amino 
acids at the C-terminus. 
2.4. Enzyme assay 
PNP activity was monitored spectrophotometrically with 
inosine as substrate and coupling with xanthine oxidase [27,29]. 
With 0.5 mM inosine as substrate in 50 mM phosphate buffer 
pH 7.0, one unit of PNP is the amount of enzyme which leads 
to phosphorolysis of one/~mol of inosine to hypoxanthine and 
ribose-l-phosphate per minute at 25°C. 
2.5. Binding constant of the inhibitor 
The inhibition constant Kj for 7-[(1,3-dihydroxypropyl- 
2)amino]ethylguanine with the calf spleen enzyme was obtained 
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Fig. I. Amino acid sequence of calf spleen PNR Respective amino acids 
in the human enzyme are given above in parentheses. Relative to human 
PNR the calf spleen enzyme is truncated at the carboxy terminus. 
Active site residues are underlined. 
as described for the human erythrocyte PNP [20]. Inhibition 
was competitive with respect o the substrate inosine, with 
Ki = 5.6 + 0.5/.tM as compared to the value of 5 + 2 ~M with 
the human enzyme [20]. The structures of both inhibitors are 
shown in Fig. 2A. 
2.6. Crystallization 
The complex of purified PNP with 7-[(1,3-dihydroxypropyl- 
2)amino]ethylguanine wasprepared by addition of an appropri- 
ate volume of PNP (20 mg/ml) to a solution of 8 mM inhibitor, 
both in 10 mM citric buffer pH 6.9 + 1 mM fl-mercaptoethanol. 
The resulting solution, containing 12 mg/ml PNP (0.3 mM in 
terms of monomer) and 2.7 mM inhibitor, was then incubated 
for 30 min at 18°C. 
Crystallization of the complex was achieved by the hanging 
drop vapour diffusion technique at 18°C using 24-well tissue 
culture Linbro plates. The reservoir solution consisted of 11- 
16% (w/v) of PEG 4000, 40 mM Tris-HCl buffer pH 8.2-8.5 and 
80 mM MgC12. The 4/t l  hanging drops consisted of 2/.tl of 
protein inhibitor complex solution and 2 fll of the reservoir 
solution. Dome shaped crystals, with dimensions up to 0.25 
mm, appeared after two weeks. 
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Fig. 2. (A) Chemical structure of 7-[(1,3-dihydroxypropyl- 
2)amino]ethylguanine. (B) Omit difference lectron density superim- 
posed with the 7-[(1,3-dihydroxypropyl-2)amino]ethylguanine model 
([IFol-lFcl[ map at 2xrms). Inhibitor model atoms were 
not included in the structure factor calculation. 
2.7. Data collection and processing 
Diffraction data were collected at 4°C on a MAR-imaging 
plate system on an Enraf-Nonius-rotating anode X-ray genera- 
tor FR 571 (40 kV, 80 mA, 3 x 0.3 mm 2 focus, graphite mono- 
chromator, CuK~ radiation), 30 frames of 1.0 ° oscillation. 
Data were processed using DENZO and SCALEPACK [30], 
R-merge = 0.11 for 6351 unique reflections for IFol- lalFol 
(99.7% of unique data in the resolution range of 38-2.9 ,/k). The 
intensities were converted to structure factor amplitudes using 
the program TRUNCATE in the CCP4 suite [31]. The esti- 
mated Bovera, from Wilson statistics is 16 A 2. The space group 
is cubic P2~3 with a = 94.02 A, V = 831910 A 3 and one mono- 
mer in the asymmetric unit. PNP forms a trimer in solution [26]; 
in the crystal structure, the 3-fold crystallographic axis relates 
monomers to trimers. 
2,8. Structure solution by molecular eplacement 
The crystal structure was solved by molecular eplacement 
using the program AMoRe [31]. The rotation search was under- 
taken with the trimer of human PNP [14] in a space group of 
lower symmetry, P212121 (resolution range 9 5 ]~), and showed 
one prominent maximum (correlation coefficient 23.1, approx- 
imately twice that of the next highest maximum). This orienta- 
tion was used to calculate the translation function for the mon- 
omer in the correct space group P2~3 (resolution range 84 /~,  
correlation coefficient 43.3). Rigid body refinement of the posi- 
tioned monomer esulted in an R-value of 42%. 
2.9. Refinement 
One refinement cycle was done employing XPLOR's [32] 
slowcooling and Powell minimization steps. Restrained least- 
squares refinement was carried out with the TNT program 
package [33] in conjunction with omit- and difference lectron 
density maps (112Fo[ - [Fc[ and [[Fo[- [Fell), which were inter- 
preted on an ESV-station using the graphical program FRODO 
[34]. 31 water sites with good hydrogen bonding eometry were 
included in the model. 
Refinement converged with an R-value of 0.21. Final geo- 
metrical quality (A, degr.): bond distance rms deviation 0.013; 
bond angle rms deviation 2.54; torsion angle rms deviation 21.5 
(not restrained in the refinement). Fig. 2B shows the omit dif- 
ference electron density for the excluded inhibitor, superim- 
posed with the final model of the inhibitor. 
3. Discussion 
The sequence of the calf spleen enzyme corresponds closely 
to that reported for human erythrocyte PNP [13], but is trun- 
cated at the carboxy terminus by 5 amino acids. The first three 
amino acids could not be conclusively sequenced for reasons 
described above. The N-terminus is neither involved in, nor 
located near, the active center. 
None of the 32 amino acid residues which differ from those 
in the human enzyme is located in the region of the active site 
(see Fig. 1). This is in line with the sequence reported for a 
bovine PNP (origin not specified and no details given), which 
exhibits 87% indentity with the human PNP and conservation 
of all amino acids in the catalytic region [35]; and is consistent 
with the similar physico-chemical and kinetic properties of the 
calf and human enzymes [12,20,26] and their similar responses 
to inhibitors [8]. 
The crystal structure of human PNP was determined with 
crystals obtained from ammonium sulphate at pH 5.5, where 
the enzyme activity is low [36]; subsequent investigations on the 
binding of inhibitors by this enzyme were severely hampered 
by the fact that the phosphate binding site was fully occupied 
by sulphate [13]. The studies on human PNP show that guanine 
0 6 hydrogen bonds to Lys244Nr/. Asn243N6 bridges 0 6, while 
N(1)-H and one of the N(2) amino hydrogens bind to 
Glu2°lOe's (Fig. 3) [13,14,35]. 
The calf spleen PNP complexed with N(7)-acycloguanosine 
crystallizes at pH 8.2-8.5 from PEG, which is almost optimal 
for enzyme activity [17]. It has the advantage that the crystals 
are free of sulphate, which should facilitate studies on the role 
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Fig. 3. Mode of binding of 7-[(1,3-dihydroxy-propyl-2)amino] 
ethylguanine in the active site of calf spleen PNP (white). Possible 
hydrogen bond lengths and angles (hydrogen positions Donor 
H... Acceptor were calculated where  possible) are: 
Inhibitor Ol7-Ser 22° O~ 2.65/~; Inhibitor O17-Arg 84 Ne 2.79 ~ (106°); 
Inhibitor OlS-Ala jl6 N 2.66/~ (138°); Inhibitor OtS-Ala H60 3.10 ~; 
Inhibitor NJ2-AIa 't60 3.11 A (152°); Inhibitor N'2-Ser 22° 02 / 3.33/k 
(151°); Inhibitor N7-Water A 3.41 /~; Inhibitor N9-Water B 3.00 ./k; 
Water B-Glu 259 O 2.32/~; Inhibitor N2Asn 243 05 2.41 A. For compar- 
ison, mode of binding of guanine in the active site of human erythrocyte 
PNP is given (black, labelled in italic) [14]. The figure drawn with 
SCHAKAL 88 [39]. 
of the phosphate binding site in binding of inhibitors/sub- 
strates. Fig. 3 depicts the binding mode of the N(7)-acyclogua- 
nosine inhibitor in the active site of calf spleen PNE As previ- 
ously predicted [20] on the basis of kinetic studies on N(7)- 
nucleoside substrates (NVGuo and N7Ino), the inhibitor binds 
in an inverted ('upside down') orientation with respect o gua- 
nine in the human PNP [14]. One of the N(2) amino hydrogens 
is bonded to Asn2430~ (Fig. 3), N(9) is bonded via a water 
molecule (W B in Fig. 3) to the peptide O of Glu 259, and N(7) 
is within bonding distance of a water molecule W A. 
The acyclic chain, which is located in the region normally 
occupied by the ribose, may be engaged in several hydrogen 
bonds with the CHz-OH hydroxyls (015 and 017) and the nitro- 
gen N 12 (Fig. 3). Since the crystals were grown at pH 8.2-8.5, 
this secondary nitrogen (pKa~9.5) should be protonated, and 
can form hydrogen bonds to SerZ2°Oy and to AIaH60. It follows 
that it is the acyclic chain which is predominantly responsible 
for binding of the inhibitor. 
These findings may have additional far reaching implica- 
tions. We have elsewhere drawn attention to the natural occur- 
rence, albeit uncommon, of purine N(7)-nucleosides and their 
substrate/inhibitor properties vs. PNP-like enzymes from vari- 
ous sources [20]. Also relevant are recent reports that 7-riboside 
derivatives of 1,3-dialkylxanthines are active antagonists in the 
A 3 receptor-mediated inhibition of adenylate cyclases, and in 
some instances are more potent and/or more specific than the 
corresponding N(9)-nucleosides [37]. The present results pro- 
vide at least a good lead to the possible binding mode of these 
agonists to the A3 receptors. Furthermore, it is worth noting 
that N(7)-acyclonucleosides of guanine xhibit significant an- 
tiherpes activities [38], the mechanisms of which remain to be 
elucidated. 
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